Cargando…

Assembly of a novel biosynthetic pathway for gentamicin B production in Micromonospora echinospora

BACKGROUND: Isepamicin is a weakly toxic but highly active aminoglycoside antibiotic derivative of gentamicin B. Gentamicin B is a naturally occurring minor component isolated from Micromonospora echinospora. 2ʹ-NH(2)-containing gentamicin C complex is a dominant compound produced by wild-type M. ec...

Descripción completa

Detalles Bibliográficos
Autores principales: Ni, Xianpu, Sun, Zhenpeng, Gu, Yawen, Cui, Hao, Xia, Huanzhang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700567/
https://www.ncbi.nlm.nih.gov/pubmed/26729212
http://dx.doi.org/10.1186/s12934-015-0402-6
_version_ 1782408338238078976
author Ni, Xianpu
Sun, Zhenpeng
Gu, Yawen
Cui, Hao
Xia, Huanzhang
author_facet Ni, Xianpu
Sun, Zhenpeng
Gu, Yawen
Cui, Hao
Xia, Huanzhang
author_sort Ni, Xianpu
collection PubMed
description BACKGROUND: Isepamicin is a weakly toxic but highly active aminoglycoside antibiotic derivative of gentamicin B. Gentamicin B is a naturally occurring minor component isolated from Micromonospora echinospora. 2ʹ-NH(2)-containing gentamicin C complex is a dominant compound produced by wild-type M. echinospora; by contrast, 2ʹ-OH-containing gentamicin B is produced as a minor component. However, the biosynthetic pathway of gentamicin B remains unclear. Considering that gentamicin B shares a unique C(2ʹ) hydroxyl group with kanamycin A, we aimed to design a new biosynthetic pathway of gentamicin B by combining twelve steps of gentamicin biosynthesis and two steps of kanamycin biosynthesis. RESULTS: We blocked the biosynthetic pathway of byproducts and generated a strain overproducing JI-20A, which was used as a precursor of gentamicin B biosynthesis, by disrupting genK and genP. The amount of JI-20A produced in M. echinospora ∆K∆P reached 911 μg/ml, which was 14-fold higher than that of M. echinospora ∆P. The enzymes KanJ and KanK necessary to convert 2ʹ-NH(2) into 2ʹ-OH from the kanamycin biosynthetic pathway were heterologously expressed in M. echinospora ΔKΔP to transform JI-20A into gentamicin B. The strain with kanJK under PermE* could produce 80 μg/ml of gentamicin B, which was tenfold higher than that of the wild-type strain. To enhance gentamicin B production, we employed different promoters and gene integration combinations. When a PhrdB promoter was used and kanJ and kanK were integrated in the genome through gene replacement, gentamicin B was generated as the major product with a maximum yield of 880 μg/ml. CONCLUSION: We constructed a new biosynthetic pathway of high-level gentamicin B production; in this pathway, most byproducts were removed. This method also provided novel insights into the biosynthesis of secondary metabolites via the combinatorial biosynthesis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12934-015-0402-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4700567
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47005672016-01-06 Assembly of a novel biosynthetic pathway for gentamicin B production in Micromonospora echinospora Ni, Xianpu Sun, Zhenpeng Gu, Yawen Cui, Hao Xia, Huanzhang Microb Cell Fact Research BACKGROUND: Isepamicin is a weakly toxic but highly active aminoglycoside antibiotic derivative of gentamicin B. Gentamicin B is a naturally occurring minor component isolated from Micromonospora echinospora. 2ʹ-NH(2)-containing gentamicin C complex is a dominant compound produced by wild-type M. echinospora; by contrast, 2ʹ-OH-containing gentamicin B is produced as a minor component. However, the biosynthetic pathway of gentamicin B remains unclear. Considering that gentamicin B shares a unique C(2ʹ) hydroxyl group with kanamycin A, we aimed to design a new biosynthetic pathway of gentamicin B by combining twelve steps of gentamicin biosynthesis and two steps of kanamycin biosynthesis. RESULTS: We blocked the biosynthetic pathway of byproducts and generated a strain overproducing JI-20A, which was used as a precursor of gentamicin B biosynthesis, by disrupting genK and genP. The amount of JI-20A produced in M. echinospora ∆K∆P reached 911 μg/ml, which was 14-fold higher than that of M. echinospora ∆P. The enzymes KanJ and KanK necessary to convert 2ʹ-NH(2) into 2ʹ-OH from the kanamycin biosynthetic pathway were heterologously expressed in M. echinospora ΔKΔP to transform JI-20A into gentamicin B. The strain with kanJK under PermE* could produce 80 μg/ml of gentamicin B, which was tenfold higher than that of the wild-type strain. To enhance gentamicin B production, we employed different promoters and gene integration combinations. When a PhrdB promoter was used and kanJ and kanK were integrated in the genome through gene replacement, gentamicin B was generated as the major product with a maximum yield of 880 μg/ml. CONCLUSION: We constructed a new biosynthetic pathway of high-level gentamicin B production; in this pathway, most byproducts were removed. This method also provided novel insights into the biosynthesis of secondary metabolites via the combinatorial biosynthesis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12934-015-0402-6) contains supplementary material, which is available to authorized users. BioMed Central 2016-01-05 /pmc/articles/PMC4700567/ /pubmed/26729212 http://dx.doi.org/10.1186/s12934-015-0402-6 Text en © Ni et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Ni, Xianpu
Sun, Zhenpeng
Gu, Yawen
Cui, Hao
Xia, Huanzhang
Assembly of a novel biosynthetic pathway for gentamicin B production in Micromonospora echinospora
title Assembly of a novel biosynthetic pathway for gentamicin B production in Micromonospora echinospora
title_full Assembly of a novel biosynthetic pathway for gentamicin B production in Micromonospora echinospora
title_fullStr Assembly of a novel biosynthetic pathway for gentamicin B production in Micromonospora echinospora
title_full_unstemmed Assembly of a novel biosynthetic pathway for gentamicin B production in Micromonospora echinospora
title_short Assembly of a novel biosynthetic pathway for gentamicin B production in Micromonospora echinospora
title_sort assembly of a novel biosynthetic pathway for gentamicin b production in micromonospora echinospora
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700567/
https://www.ncbi.nlm.nih.gov/pubmed/26729212
http://dx.doi.org/10.1186/s12934-015-0402-6
work_keys_str_mv AT nixianpu assemblyofanovelbiosyntheticpathwayforgentamicinbproductioninmicromonosporaechinospora
AT sunzhenpeng assemblyofanovelbiosyntheticpathwayforgentamicinbproductioninmicromonosporaechinospora
AT guyawen assemblyofanovelbiosyntheticpathwayforgentamicinbproductioninmicromonosporaechinospora
AT cuihao assemblyofanovelbiosyntheticpathwayforgentamicinbproductioninmicromonosporaechinospora
AT xiahuanzhang assemblyofanovelbiosyntheticpathwayforgentamicinbproductioninmicromonosporaechinospora